
Caris AI Study Links Treatment Selection to Longer Survival in Pancreatic Cancer
01
Utilize AI-guided treatment selection to enhance survival rates in pancreatic cancer patients.
02
Identify patients likely to benefit from FOLFIRINOX over gemcitabine plus nab-paclitaxel with molecular data.
03
Achieve a median overall survival of 16.0 months with FOLFIRINOX versus 9.9 months with gem/nab-p.
04
Leverage insights from Caris study to improve personalized treatment strategies for advanced pancreatic cancer.
The full story
Caris AI Study Links Treatment Selection to Longer Survival in Pancreatic Cancer
Read the story
Next storyIntermountain Medical Center Deploys AI-Powered MRI To Speed Up ScansMore visual stories Slide 1 of 6